The utilization of αGITR antibodies to mitigate Tregs functionality has been discovered to induce the differentiation of CD4+T cells into effector T cells, diminish Tregs-mediated immune suppression, and generate anti-tumor impacts (Zenga et al., 2022). Here, CD4 is linked to neoplasm.